A Phase Ib, open-label, dose-finding study of the JAK inhibitor INC424 tablets administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) and baseline platelet counts ≥ 50 x109/L and <100 x109/L

Trial Profile

A Phase Ib, open-label, dose-finding study of the JAK inhibitor INC424 tablets administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) and baseline platelet counts ≥ 50 x109/L and <100 x109/L

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Acronyms The EXPAND Study
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 22 Jan 2016 Planned number of patients changed from 62 to 72 as per ClinicalTrials.gov record.
    • 22 Jan 2016 Planned End Date changed from 1 Dec 2017 to 1 Sep 2020 as per ClinicalTrials.gov record.
    • 22 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2020 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top